Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00000637 | A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children | PHASE3 | COMPLETED | 819 | — | — | - | Sep 1, 1996 | Nov 2, 2021 | 80 | United States, Puerto Rico |
| NCT00000671 | A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment | PHASE2 | COMPLETED | 750 | — | — | - | - | Mar 14, 2011 | 71 | United States, Puerto Rico |
| NCT00001029 | A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past | PHASE2 | COMPLETED | 654 | — | — | - | May 1, 1993 | Nov 4, 2021 | 37 | United States, Puerto Rico +1 |
| Name | Type | Description |
|---|---|---|
| Zidovudine | DRUG | - |
| Didanosine | DRUG | - |
| Zalcitabine | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Acetaminophen, ibuprofen, or aspirin, but not on a continual basis for \> 72 hours. * Systemic ketoconazole and fluconazole for acute therapy. Recommended: * Prophylaxis for PCP. (Primary prophylaxis with TMP / SMX is encouraged.) IV pentamid...